Published in J Pharmacokinet Pharmacodyn on August 01, 2012
A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood (2015) 1.40
A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback. J Math Biol (2013) 0.84
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models. CPT Pharmacometrics Syst Pharmacol (2015) 0.83
Parameter Identifiability of Fundamental Pharmacodynamic Models. Front Physiol (2016) 0.79
An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects. Invest New Drugs (2014) 0.79
A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations. AAPS J (2015) 0.78
Cross-membrane signal transduction of receptor tyrosine kinases (RTKs): from systems biology to systems pharmacology. J Math Biol (2012) 0.78
Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition. CPT Pharmacometrics Syst Pharmacol (2014) 0.77
Pattern Recognition in Pharmacokinetic Data Analysis. AAPS J (2015) 0.76
Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. J Pharmacokinet Pharmacodyn (2015) 0.75
FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition. Pharm Res (2016) 0.75
AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol (2017) 0.75
Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain. Br J Clin Pharmacol (2016) 0.75
Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site. J Pharmacokinet Pharmacodyn (2017) 0.75
Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci (2004) 4.28
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn (2001) 3.21
Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn (2008) 1.97
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res (2005) 1.96
Target-mediated drug disposition and dynamics. Biochem Pharmacol (2006) 1.85
On the validity of the steady state assumption of enzyme kinetics. Bull Math Biol (1988) 1.67
Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther (1994) 1.64
Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn (2009) 1.33
Cell surface receptors for signal transduction and ligand transport: a design principles study. PLoS Comput Biol (2007) 1.21
Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm (1999) 1.13
Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. Pharm Res (2002) 1.03
Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J Pharmacokinet Pharmacodyn (2009) 1.01
Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. J Theor Biol (2011) 0.99
Impact of plasma-protein binding on receptor occupancy: an analytical description. J Theor Biol (2008) 0.97
Theoretical considerations of target-mediated drug disposition models: simplifications and approximations. Pharm Res (2011) 0.97
Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.94
Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm Res (1989) 0.93
Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn (2009) 0.91
Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn (2009) 0.89
Dynamics of target-mediated drug disposition. Eur J Pharm Sci (2009) 0.89
MDMA: on the translation from rodent to human dosing. Psychopharmacology (Berl) (2009) 1.54
A modeling approach for compounds affecting body composition. J Pharmacokinet Pharmacodyn (2013) 0.89
Dynamics of target-mediated drug disposition. Eur J Pharm Sci (2009) 0.89
Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs. J Pharmacol Toxicol Methods (2005) 0.89
Volume turnover kinetics of fluid shifts after hemorrhage, fluid infusion, and the combination of hemorrhage and fluid infusion in sheep. Anesthesiology (2005) 0.88
Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions. J Pharmacokinet Pharmacodyn (2013) 0.87
Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. Future Med Chem (2009) 0.85
Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acid. J Pharm Sci (2014) 0.85
Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels. Eur J Pharm Sci (2006) 0.85
Turnover modeling of non-esterified fatty acids in rats after multiple intravenous infusions of nicotinic acid. Dose Response (2009) 0.84
A pharmacodynamic turnover model capturing asymmetric circadian baselines of body temperature, heart rate and blood pressure in rats: challenges in terms of tolerance and animal-handling effects. J Pharmacokinet Pharmacodyn (2005) 0.84
Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole. J Pharmacokinet Pharmacodyn (2002) 0.84
Feedback modeling of non-esterified fatty acids in rats after nicotinic acid infusions. J Pharmacokinet Pharmacodyn (2010) 0.83
Quantitative analysis of rate and extent of tolerance of biomarkers: application to nicotinic acid-induced changes in non-esterified fatty acids in rats. Eur J Pharm Sci (2011) 0.82
Challenges of a mechanistic feedback model describing nicotinic acid-induced changes in non-esterified fatty acids in rats. J Pharmacokinet Pharmacodyn (2013) 0.82
Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats. AAPS J (2015) 0.81
A dynamical systems analysis of the indirect response model with special emphasis on time to peak response. J Pharmacokinet Pharmacodyn (2005) 0.81
A novel approach to data processing of the QT interval response in the conscious telemetered beagle dog. J Pharmacol Toxicol Methods (2006) 0.81
Modeling drug- and system-related changes in body temperature: application to clomethiazole-induced hypothermia, long-lasting tolerance development, and circadian rhythm in rats. J Pharmacol Exp Ther (2005) 0.81
Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. J Pharmacol Toxicol Methods (2007) 0.80
Modeling energy intake by adding homeostatic feedback and drug intervention. J Pharmacokinet Pharmacodyn (2014) 0.80
Studies of drug binding to plasma proteins using a variant of equilibrium dialysis. J Pharm Biomed Anal (2005) 0.79
Rapid and long-lasting tolerance to clomethiazole-induced hypothermia in the rat. Eur J Pharmacol (2005) 0.76
Nonlinear turnover models for systems with physiological limits. Eur J Pharm Sci (2008) 0.75